Table 1.
Demographic, physiologic and clinical characteristics s of n=611 asthma subjects.
| Characteristic | Number (%), Mean ± SD |
|---|---|
| Gender (females) | 395 (65%) |
| Age (years) | 47±14 |
| BMI (kg/m2) | 30±8 (range: 17-62) |
| Obese (BMI≥30) | 249 (41%) |
| Race: | |
| African-Americans | 31 (5%) |
| Caucasians | 562 (92%) |
| Others* | 18 (3%) |
| Current smokers | 28 (5%) |
| FEV1% predicted | 92±19 |
| FEV1/FVC | 77±9 |
| FEF25-75% predicted | 68±31 |
| Asthma Step: | |
| 1 | 297 (49%) |
| 2 | 69 (11%) |
| 3 | 134 (22%) |
| 4 | 111 (18%) |
| Habitual sleep duration (h): | 7.16±1.57 |
| very short (<6h) | 68 (11%) |
| short (≥6 and <7h) | 144 (24%) |
| normal (7-8h) | 308 (50%) |
| long (>8 and ≤9h) | 51 (8%) |
| very long (>9h) | 40 (7%) |
| History of rhinitis | 559 (91%) |
| History of chronic sinusitis | 193 (32%) |
| History of nasal polyps | 93 (15%) |
| History of psychiatric disease | 158 (26%) |
| History of GERD | 281 (46%) |
| Using inhaled corticosteroids (ICS) | 471 (77%) |
| ICS dose: | |
| low | 142 (23%) |
| medium | 176 (29%) |
| high | 153 (25%) |
| Using oral corticosteroids | 49 (8%) |
| Using inhaled long acting β2-agonist (LABA) | 371 (61%) |
| Using leukotriene modifiers (LTM) | 156 (26%) |
| Using theophylline | 11 (2%) |
*
included Asians, Hawaiian/Pacific Islanders and American Indians/Alaskans.
SD= standard deviation; BMI= body mass index; FEV1%= forced expiratory volume in the first second of the FVC maneuver; FVC%= forced vital capacity; FEF 25-75%= forced expiratory flow between 25% and 75% of vital capacity (all these physiologic variables are expressed as percentages of predicted values); GERD= gastroesophageal reflux disease.